Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Marshall Edwards today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, fast track status for its intended use in patients with hormone- refractory prostate cancer (HRPC).
An initial validation study presented by Exagen Diagnostics at the San Antonio Breast Cancer Symposium suggests it may soon be possible to distinguish good prognosis from poor prognosis in any newly diagnosed breast cancer patient based on DNA changes in the patient's tumor.
The Endocrine Society, which represents more than 12,000 endocrinologists who are specially trained to diagnose, treat and conduct basic and clinical research on complex hormonal disorders, has called for new clinical guidelines on the use of androgens in women/female sexual dysfunction.
A new study finds that only 36% of cancer patients ages 65 and older participate in clinical trials, despite making up 60% of the U.S. cancer population. The study will be published November 15 in the Journal of Clinical Oncology (JCO).
Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.
Early stage breast cancer patients over the age of 50 can greatly minimize their chances of recurrence after surgery by receiving radiation therapy in addition to taking tamoxifen, a hormonal therapy
New hope was offered today to men with advanced prostate cancer that no longer responds to hormone therapy – a persistent problem in prostate cancer treatment.
The first study to compare survival between women with breast cancer whose treatment was based on consensus guidelines and those whose treatment was not shows that adhering to established guidelines improves survival and reduces the risk of recurrence.
High-risk prostate cancer patients who undergo a combination of hormonal therapy, radioactive seed implant (also called brachytherapy) and external beam radiation therapy are shown to have an increased chance of cancer cure
Chemicals that inhibit the development of new blood vessels could prove to be a new way of treating endometriosis, according to research from The Netherlands and the USA presented today (Monday 28 June) at the 20th annual meeting of the European Society of Human Reproduction and Embryology.
Men with aggressive, metastatic prostate cancer who receive immediate early hormone therapy live on average three to four years longer than others who delay similar treatment, according to researchers at the University of Rochester.
Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.
Recent clinical studies led by Johns Hopkins Kimmel Cancer Center researchers have found that a drug called atrasentan reduces the risk by 20 percent that cancer will progress in men with advanced hormone-resistant prostate cancer.
According to a new online survey of women with heavy periods, women have strong opinions about what they want – and what they don't want to do – to manage their heavy periods.